Intravenous tissue plasminogen activator treatment for ischemic stroke in dabigatran-treated patients

Acta Neurochirurgica

Volumn 154, Issue 1, 2012, Pages 87-

  Takeuchi, Satoru ^a   Wada, Kojiro ^a   Nagatani, Kimihiro ^a   Otani, Naoki ^a   Osada, Hideo ^a   Nawashiro, Hiroshi ^a  

^a NATIONAL DEFENSE MEDICAL COLLEGE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

DABIGATRAN; TISSUE PLASMINOGEN ACTIVATOR; WARFARIN;

BLEEDING TENDENCY; BLOOD CLOT LYSIS; BLOOD CLOTTING TIME; BRAIN EMBOLISM; BRAIN HEMORRHAGE; BRAIN ISCHEMIA; CONCENTRATION RESPONSE; DISEASE ASSOCIATION; DISEASE CONTROL; DISEASE COURSE; DISEASE PREDISPOSITION; DRUG INDICATION; DRUG MONITORING; DRUG SAFETY; GASTROINTESTINAL HEMORRHAGE; HUMAN; IN VITRO STUDY; INTERNATIONAL NORMALIZED RATIO; LETTER; PATIENT SELECTION; PRACTICE GUIDELINE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK FACTOR; RISK REDUCTION; THROMBIN TIME;

ANTICOAGULANTS; BENZIMIDAZOLES; BETA-ALANINE; BRAIN ISCHEMIA; FIBRINOLYTIC AGENTS; HUMANS; INJECTIONS, INTRAVENOUS; RISK FACTORS; STROKE; TISSUE PLASMINOGEN ACTIVATOR;

EID: 84856293399     PISSN: 00016268     EISSN: 09420940     Source Type: Journal    
DOI: 10.1007/s00701-011-1196-x     Document Type: Letter

References (6)

1. CT Ammollo F Semeraro F Incampo N Semeraro M Colucci 2010 Dabigatran enhances clot susceptibility to fibrinolysis by mechanisms dependent on and independent of thrombin-activatable fibrinolysis inhibitor Thromb Haemost 8 790 798 10.1111/j.1538-7836.2010.03739.x 1:CAS:528:DC%2BC3cXlvVGksLY%3D
2. SJ Connolly MD Ezekowitz S Yusuf J Eikelboom J Oldgren A Parekh J Pogue PA Reilly E Themeles J Varrone S Wang M Alings D Xavier J Zhu R Diaz BS Lewis H Darius HC Diener CD Joyner L Wallentin RE-LY Steering Committee and Investigators 2009 Dabigatran versus warfarin in patients with atrial fibrillation N Engl J Med 361 1139 1151 19717844 10.1056/NEJMoa0905561 1:CAS:528:DC%2BD1MXhtFOjsLnN
3. A De Smedt S De Raedt K Nieboer J De Keyser R Brouns 2010 Intravenous thrombolysis with recombinant tissue plasminogen activator in a stroke patient treated with dabigatran Cerebrovasc Dis 30 533 534 20881383 10.1159/000319886
4. KH Liesenfeld HG Schäfer IF Trocóniz C Tillmann BI Eriksson J Stangier 2006 Effects of the direct thrombin inhibitor dabigatran on ex vivo coagulation time in orthopaedic surgery patients: a population model analysis Br J Clin Pharmacol 62 527 537 17061960 10.1111/j.1365-2125.2006.02667.x 1:CAS:528:DC%2BD28XhtlakurnK (Pubitemid 44571573)
5. MC Matute M Guillán J García-Caldentey J Buisan M Aparicio J Masjuan M Alonso de Leciñana 2011 Thrombolysis treatment for acute ischaemic stroke in a patient on treatment with dabigatran Thromb Haemost 106 178 179 21505718 10.1160/TH11-01-0042 1:CAS:528:DC%2BC3MXpvFerurc%3D
6. MD Vergouwen LK Casaubon RH Swartz J Fang M Stamplecoski MK Kapral FL Silver Investigators of the Registry of the Canadian Stroke Network 2011 Subtherapeutic warfarin is not associated with increased hemorrhage rates in ischemic strokes treated with tissue plasminogen activator Stroke 42 1041 1045 21350204 10.1161/STROKEAHA.110.599183 1:CAS:528:DC%2BC3MXjvVOjs7g%3D